Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Trial of Pazopanib to Evaluate the Activity and Tolerability in Patients With Advanced and/or Metastatic Liposarcoma Who Have Relapsed Following Standard Therapies or for Whom no Standard Therapy Exists

NCT01692496 is registered in ClinicalTrials.gov with Grupo Espanol de Investigacion en Sarcomas as lead sponsor.

NCT NCT01692496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01692496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Trial of Pazopanib to Evaluate the Activity and Tolerability in Patients With Advanced and/or Metastatic Liposarcoma Who Have Relapsed Following Standard Therapies or for Whom no Standard Therapy Exists
Lead sponsor
Grupo Espanol de Investigacion en Sarcomas
Phase
Phase 2
Overall status
Completed
Start date
January 29, 2013
Completion date
March 2, 2018
Enrollment
52 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

advanced and / or metastatic liposarcoma